Exelixis Inc Convertible Debt, Noncurrent
Exelixis Inc (EXEL) had Convertible Debt, Noncurrent of $0 as of 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation › Long-Term Debt, Excluding Current Maturities
us-gaap:ConvertibleDebtNoncurrent · last filed 2017-02-27
- 2016-12-31: Convertible Debt, Noncurrent $0.00.
- 2016-09-30: Convertible Debt, Noncurrent $81.49M.
- 2016-06-30: Convertible Debt, Noncurrent $288.56M.
- 2016-03-31: Convertible Debt, Noncurrent $281.16M.
| Period end | Convertible Debt, Noncurrent | Convertible Debt, Noncurrent as first filed |
|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-02-27 | |
| 2016-09-30 | $81.49M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $288.56M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $281.16M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $337.94M 10-K · filed 2017-02-27 | $301.44M 10-K · filed 2016-02-29 |
| 2015-09-30 | $297.44M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $291.23M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $284.36M 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $223.63M 10-K · filed 2017-02-27 | $182.40M 10-K · filed 2015-03-02 |
| 2014-09-30 | $177.96M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $173.63M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $261.41M 10-Q · filed 2014-05-01 | |
| 2013-12-31 | $301.55M 10-K · filed 2017-02-27 | $255.15M 10-K · filed 2014-02-20 |
| 2013-09-30 | $248.71M 10-Q · filed 2013-10-30 | |
| 2013-06-30 | $242.46M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $236.38M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $291.83M 10-K · filed 2017-02-27 | $240.48M 10-K · filed 2013-02-21 |
| 2012-09-30 | $239.24M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $85.86M 10-Q · filed 2012-08-02 | |
| 2012-03-31 | $83.58M 10-Q · filed 2012-05-03 | |
| 2011-12-31 | $91.39M 10-K · filed 2013-02-21 | |
| 2011-09-30 | $89.30M 10-Q · filed 2011-10-27 | |
| 2011-06-30 | $87.29M 10-Q · filed 2011-08-04 | |
| 2010-12-31 | $83.40M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |